HER2 Support Group Forums - View Single Post - Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of mal

News · 12-08-2014, 11:30 AM

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

More...

12-08-2014, 11:30 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,149	Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of mal Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. More...